Yunsuk Choi

Yunsuk Choi

Auto-generated profile, based on publicly available information

Yunsuk Choi

Department of Hematology Asan Medical Center, University of Ulsan College of Medicine Seoul Korea

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2009 in Lung Cancer
Verified
Journal Article
Closed access
JKJeong-Eun Kim
Jeong-Eun Kim
DLDae Ho Lee
Dae Ho Lee
YCYunsuk Choi
Yunsuk Choi
DYDok Hyun Yoon
Dok Hyun Yoon
SKSang-We Kim
Sang-We Kim
JLJung-Shin Lee
Jung-Shin Lee

3 October 2016 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
JJJae-Cheol Jo
Jae-Cheol Jo
MKMisung Kim
Misung Kim
YCYunsuk Choi
Yunsuk Choi
HKHyun-Jung Kim
Hyun-Jung Kim
JKJi Eun Kim
Ji Eun Kim
HCHee Jeong Cha
Hee Jeong Cha

20 August 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JLJe-Hwan Lee
Je-Hwan Lee
HKHawk Kim
Hawk Kim
YJYoung-Don Joo
Young-Don Joo
WLWon-Sik Lee
Won-Sik Lee
SBSung Hwa Bae
Sung Hwa Bae
FHfor the Cooperative Study Group A for Hematology
for the Cooperative Study Group A for Hematology
Purpose: We compared two induction regimens, idarubicin (12 mg/m2/d for 3 days) versus high-dose daunorubicin (90 mg/m2/d for 3 days), in young adults with newly diagnosed acute myeloid leukemia (AML). Patients and Methods: A total of 299 patients (149 randomly assigned to cytarabine plus idarubicin [AI] and 150 assigned to cytarabine plus high-dose daunorubicin [AD]) were analyzed. All patients received cytarabine (200 mg/m2/d for 7 days). Results: Complete remission (CR) was induced in 232 patients (77.6%), with no difference in CR rates between the AI and AD arms (80.5% v 74.7%, respectively; P = .224). At a median follow-up time of 34.9 months, survival and relapse rates did not differ between the AI and AD arms (4-year overall survival, 51.1% v 54.7%, respectively; P = .756; cumulative incidence of relapse, 35.2% v 25.1%, respectively; P = .194; event-free survival, 45.5% v 50.8%, respectively; P = .772). Toxicity profiles were also similar in the two arms. Interestingly, overall and event-free survival times of patients with FLT3 internal tandem duplication (ITD) mutation were significantly different (AI v AD: median overall survival, 15.5 months v not reached, respectively; P = .030; event-free survival, 11.9 months v not reached, respectively; P = .028). Conclusion: This phase III trial comparing idarubicin with high-dose daunorubicin did not find significant differences in CR rates, relapse, and survival. Significant interaction between the treatment arm and the FLT3-ITD mutation was found, and high-dose daunorubicin was more effective than idarubicin in patients with FLT3-ITD mutation.

10 November 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SHSook-Kyoung Heo
Sook-Kyoung Heo
ENEui-Kyu Noh
Eui-Kyu Noh
JKJeong Yi Kim
Jeong Yi Kim
YJYoo Kyung Jeong
Yoo Kyung Jeong
JJJae-Cheol Jo
Jae-Cheol Jo
HKHawk Kim
Hawk Kim
Dasatinib and radotinib are oral BCR-ABL tyrosine kinase inhibitors that were developed as drugs for the treatment of chronic myeloid leukemia. We report here that the c-KIT (CD117) targeting with dasatinib and radotinib promotes acute myeloid leukemia (AML) cell death, and c-KIT endocytosis is essential for triggering c-KIT-positive AML cell death by dasatinib and radotinib during the early stages. In addition, dasatinib and radotinib reduce heat shock protein 90β (HSP90β) expression and release Apaf-1 in c-KIT-positive AML cells. Finally, this activates a caspase-dependent apoptotic pathway in c-KIT-positive AML cells. Moreover, the inhibition of c-KIT endocytosis by dynamin inhibitor (DY) reversed cell viability and c-KIT expression by dasatinib and radotinib. HSP90β expression was recovered by DY in c-KIT-positive AML cells as well. Furthermore, the effect of radotinib on c-KIT and HSP90β showed the same pattern in a xenograft animal model using HEL92.1.7 cells. Therefore, dasatinib and radotinib promote AML cell death by targeting c-KIT. Taken together, these results indicate that dasatinib and radotinib treatment have a potential role in anti-leukemic therapy on c-KIT-positive AML cells.

1 August 2011 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
SKSung-Doo Kim
Sung-Doo Kim
JLJe-Hwan Lee
Je-Hwan Lee
EHEun-Hye Hur
Eun-Hye Hur
JLJung-Hee Lee
Jung-Hee Lee
DKDae-Young Kim
Dae-Young Kim
KLKyoo-Hyung Lee
Kyoo-Hyung Lee
Intravenous (i.v.) busulfan can produce a more consistent pharmacokinetic profile than oral formulations can, but nonetheless, significant interpatient variability is evident. We investigated the influence of polymorphisms of 3 GST isozyme genes (GSTA1, GSTM1, and GSTT1) on i.v. busulfan clearance. Fifty-eight adult patients who received 3.2 mg/kg/day of busulfan as conditioning for hematopoietic cell transplantation were included in this study. Stepwise multiple linear regression demonstrated that GSTA1 variant GSTA1∗B (P = .004), GSTM1/GSTT1 double-null genotype (P = .039), and actual body weight (P = .001) were significantly associated with lower clearance of i.v. busulfan. A trend test analyzing the overall effect of GST genotype on busulfan pharmacokinetics, combining GSTA1 gene polymorphism and the number of GSTM1- and GSTT-null genotypes, showed a significant correlation between GST genotype and busulfan clearance (P = .001). The clearance of i.v. busulfan was similar between patients with GSTA1∗A/∗A and GSTM1/GSTT1 double-null genotypes and those with GSTA1∗A/∗B and GSTM1/GSTT1 double-positive genotypes. In conclusion, a pharmacogenetic approach using GST gene polymorphisms may be valuable in optimizing the i.v. busulfan dosage scheme. Our results also highlight the importance of including polygenic analyses and addressing interactions among isozyme genes in pharmacogenetic studies.

1 February 2011 in Leukemia Research
Verified
Journal Article
Closed access
DKDae-Young Kim
Dae-Young Kim
JLJe-Hwan Lee
Je-Hwan Lee
JLJung-Hee Lee
Jung-Hee Lee
SKSung-Doo Kim
Sung-Doo Kim
SLSung-Nam Lim
Sung-Nam Lim
KLKyoo-Hyung Lee
Kyoo-Hyung Lee